Magnoflorine

Pharmacology & Research

Magnoflorine is a quaternary aporphine (isoquinoline) alkaloid — a common co-alkaloid with berberine in Berberis root, and co-dominant in muira puama bark ^{2Reference 22020Advances in the chemistry and bioactivity of magnoflorine and magnoflorine-containing extractsView study →}. One physicochemical fact governs the whole page: the nitrogen carries a permanent positive charge, so magnoflorine is poorly absorbed orally and barely crosses the blood-brain barrier — which undercuts its reported CNS effects. Its literature is modest and entirely preclinical (anxiolytic, anti-inflammatory, metabolic, hypotensive signals), and one safety accuracy point is critical: magnoflorine occurs in some Aristolochia species, but it is not aristolochic acid — that plant’s nephrotoxic/carcinogenic principle is a chemically unrelated molecule.

1. Anxiolytic / sedative

Magnoflorine reduced anxiety-like behaviour and had sedative effects in mice (identified as a sedative constituent of Sinomenium) ^{3Reference 32013AnimalThe involvement of magnoflorine in the sedative and anxiolytic effects of Sinomeni Caulis et Rhizoma in miceView study →}, with separate rodent work reporting improved cognition in an Alzheimer’s model (JNK inhibition) ^{4Reference 42023Magnoflorine improves cognitive deficits and pathology of Alzheimer’s disease by inhibiting JNK signallingView study →} and reduced neuronal injury in cerebral ischaemia (autophagy/Sirt1/AMPK) ^{5Reference 52022Magnoflorine attenuates cerebral-ischemia-induced neuronal injury via autophagy/Sirt1/AMPKView study →}.

Gap: all preclinical, and the quaternary (permanently charged) structure gives poor blood-brain-barrier penetration — so oral CNS claims are weak absent central or high-dose administration ^{3,5Reference 32013AnimalThe involvement of magnoflorine in the sedative and anxiolytic effects of Sinomeni Caulis et Rhizoma in miceView study →Reference 52022Magnoflorine attenuates cerebral-ischemia-induced neuronal injury via autophagy/Sirt1/AMPKView study →}.

2. Anti-inflammatory / immunomodulatory

Magnoflorine ameliorated collagen-induced arthritis ^{6Reference 62023Magnoflorine ameliorates collagen-induced arthritis by suppressing inflammation via NF-κB/MAPKView study →} and LPS-induced acute lung injury ^{7Reference 72018Magnoflorine ameliorates LPS-induced acute lung injury via suppressing NF-κB and MAPKView study →} by suppressing NF-κB and MAPK signalling.

Gap: the direction of effect is not clean — in U937 macrophages magnoflorine enhanced LPS-driven pro-inflammatory responses via MyD88 ^{8Reference 82018Magnoflorine enhances LPS-activated pro-inflammatory responses via MyD88-dependent pathways in U937 macrophagesView study →}; it is context-dependent, with no human data ^{6,8Reference 62023Magnoflorine ameliorates collagen-induced arthritis by suppressing inflammation via NF-κB/MAPKView study →Reference 82018Magnoflorine enhances LPS-activated pro-inflammatory responses via MyD88-dependent pathways in U937 macrophagesView study →}.

3. Metabolic

Magnoflorine prevented skeletal-muscle atrophy in streptozotocin-diabetic rats via Akt/mTOR/FoxO ^{9Reference 92021AnimalMagnoflorine prevents skeletal-muscle atrophy via Akt/mTOR/FoxO in streptozotocin-induced diabetic ratsView study →}, and it is catalogued among aporphine alkaloids with metabolic-syndrome potential ^{10Reference 102021Natural aporphine alkaloids with potential to impact metabolic syndromeView study →}.

Gap: a single primary model plus a narrative review, with no glycaemic trial (contrast berberine, where human data actually exist) ^{9,10Reference 92021AnimalMagnoflorine prevents skeletal-muscle atrophy via Akt/mTOR/FoxO in streptozotocin-induced diabetic ratsView study →Reference 102021Natural aporphine alkaloids with potential to impact metabolic syndromeView study →}.

4. Cardiovascular (hypotensive)

Magnoflorine was characterised as a hypotensive principle in mid-20th-century alkaloid pharmacology ^{11Reference 111964Pharmacological studies on magnoflorine, a hypotensive principleView study →}.

Gap: old, largely parenteral animal studies with an underspecified mechanism, not reproduced in modern controlled work ^{11Reference 111964Pharmacological studies on magnoflorine, a hypotensive principleView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
NF-κB / MAPK signalling	suppressed (rodent arthritis, lung injury)	anti-inflammatory
MyD88-dependent TLR signalling	enhanced pro-inflammatory response (macrophages)	contradictory immunomodulation (honesty flag)
JNK; autophagy / Sirt1 / AMPK	inhibited; activated	cognition / neuroprotection
Akt / mTOR / FoxO	modulated (↑ slow-MyHC, diabetic muscle)	anti-atrophy / metabolic
Vascular (mechanism underspecified)	hypotensive	cardiovascular
Radical scavenging (in vitro)	antioxidant	supportive

No single well-validated molecular target; effects are pathway-level and mostly preclinical.

Pharmacokinetics

Load-bearing. Magnoflorine is a quaternary aporphine alkaloid whose nitrogen carries a permanent positive charge, so as a fixed cation it has low passive membrane permeability, low oral bioavailability and poor blood-brain-barrier penetration ^{1Reference 12020ReviewMagnoflorine: a review of its pharmacology, pharmacokinetics and toxicityView study →}. Rat studies show rapid absorption but low systemic exposure with wide tissue distribution and extensive metabolism ^{12Reference 122015AnimalPharmacokinetics in rats and tissue distribution in mice of magnoflorine by UPLC-MS/MSView study →}, and it is a marker/interacting constituent in multi-herb decoctions where matrix effects alter its exposure. The implication: the CNS applications above depend on crossing a barrier this molecule crosses poorly, which is a major reason the anxiolytic/cognitive claims stay weak absent central or high-dose administration.

Clinical trials

There are no human trials of isolated magnoflorine for any indication. Human exposure is only as a minor constituent of multi-herb formulas (Sinomenium, Gegen-Qinlian, muira puama, barberry preparations), where effects cannot be attributed to magnoflorine; all efficacy data are cell-based or rodent. Scattered cytotoxicity in cancer cell lines has also been reported ^{13Reference 132020Magnoflorine — isolation and anticancer potential against NCI-H1299, MDA-MB-468, T98G and TE671 cellsView study →}.

Last checked: July 2026.

Toxicity & Safety

Magnoflorine has a low toxicity verdict (with preclinical uncertainty): as a quaternary alkaloid it is poorly absorbed orally, which keeps acute oral toxicity low, and the pharmacology/pharmacokinetics/toxicity review reports no major toxicity signal at studied doses ^{1Reference 12020ReviewMagnoflorine: a review of its pharmacology, pharmacokinetics and toxicityView study →}. It is not inert, however — classical studies show a parenteral hypotensive action ^{11Reference 111964Pharmacological studies on magnoflorine, a hypotensive principleView study →}, and the benzylisoquinoline family in these plants includes curare-type neuromuscular agents, so injected or high systemic exposure is not benign and human toxicology is essentially uncharacterised. Critical accuracy point: magnoflorine ≠ aristolochic acid. Magnoflorine is found in some Aristolochia species, but the renal toxicity and carcinogenicity of Aristolochia are caused by aristolochic acid, a chemically unrelated compound — that hazard must not be transferred to magnoflorine.

Pregnancy & lactation

Not researched — avoid. There are no reproductive or developmental data for isolated magnoflorine, and some botanical sources carry independent pregnancy cautions, so it is best avoided in pregnancy and lactation.

Dosage

There is no established human dose — no isolate dosing exists. Preclinical work uses mg/kg rodent doses (oral and parenteral) that do not translate to a human recommendation, so no dose should be inferred.

References